Get started
PFIZERPFIZERPFIZER

PFIZER

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

1PFE trade ideas

A Strategic Technical Outlook for Pfizer.Pfizer, Inc. (PFE) has shown a notable rebound in its stock price, as observed in the latest trading sessions. This analysis delves into various technical indicators and chart patterns to forecast future price movements and provide strategic trading recommendations. PFE has recently experienced a bullish surge, evident from the significant green candle that broke above several key resistance levels. This bullish momentum is further corroborated by high trading volume, indicating strong buying interest. Moving Averages: The stock is currently trading above its key moving averages, including the 10-day, 20-day, and 50-day exponential moving averages (EMAs), which are all trending upwards, signaling a bullish outlook in the short term. MACD (Moving Average Convergence Divergence): The MACD line crossing above the signal line suggests increasing bullish momentum. The histogram entering the positive territory further reinforces this bullish sentiment. RSI (Relative Strength Index): The RSI is currently at 64.34, which is near the upper threshold but still below the overbought zone (70), indicating that there is room for upward movement before the stock becomes technically overbought. Stochastic Oscillator: The Stochastic RSI being at 100 indicates overbought conditions on a very short-term basis, suggesting a potential temporary pullback or consolidation may occur before further upward movement. Fibonacci Retracement: The recent surge has pushed the price above the 38.2% Fibonacci retracement level of the last major downswing, targeting the next resistance near the 50% level. Short-Term Bullish Target: If the bullish momentum continues, PFE could test the next resistance at $28.50, marked by the 50% Fibonacci retracement level. A breakout above this level could extend gains towards $29.30, corresponding to the 61.8% retracement level. Support Levels: Immediate support is found at $26.80, with further cushion at $26.20, which aligns with the recent breakout point. Long Entry: Consider going long if the price dips towards $26.80, using a stop loss at $26.20 to protect against unexpected downturns. This position benefits from potential upward movement, with a primary target at $28.50 and a secondary target at $29.30. Short Position: Traders might consider short positions if the price fails to sustain above the $28.50 resistance, with a tight stop loss just above this level at $28.80. The aim would be to capitalize on potential retracements towards the $27.00 mark. Pfizer's technical setup presents a compelling bullish case in the short to medium term, supported by robust volume and favorable technical indicators. However, traders should remain vigilant of potential overbought conditions that could prompt price corrections. Monitoring key resistance and support levels will be crucial for timely trade execution, optimizing both entry and exit points.
NYSE:PFE
by AxiomEx
Pfizer Surges as Earnings Soar Above ExpectationsPfizer Inc. ( NYSE:PFE ) sent shockwaves through the market with a stunning first-quarter performance, catapulting its stock price upward following a robust quarterly beat that surpassed analysts' expectations by a wide margin. The pharmaceutical giant reported adjusted earnings of 82 cents per share, significantly outpacing the forecasted 51 cents per share, and raking in $14.88 billion in revenue, well above the anticipated $13.87 billion. This impressive feat marks a stark turnaround from the previous year's earnings of $1.23 per share on $18.49 billion in sales. Investors reacted positively to Pfizer's optimistic outlook for the year, as the company raised its earnings guidance and maintained its sales forecast. With a projected adjusted profit range of $2.15 to $2.35 per share and sales expected to reach between $58.5 billion and $61.5 billion, Pfizer is poised for a strong fiscal year ahead. Key drivers behind Pfizer's stellar performance include aggressive cost-cutting measures and resilient demand for its COVID-19 products, particularly its vaccine Comirnaty, developed in collaboration with BioNTech. Despite a significant drop in sales of the oral antiviral Paxlovid, which fell 50% to $2.04 billion, Pfizer remains optimistic about the prospects of its COVID portfolio, expecting $8 billion in combined sales from its COVID-19 products. The success of Pfizer's strategic acquisitions, notably the $43 billion deal for Seagen, is evident in the robust sales of cancer treatment Padcev and the continued growth of its pipeline. However, challenges persist, as sales of targeted cancer therapy Adcetris fell short of expectations, underscoring the need for sustained new launch performance. Attention is also focused on Pfizer's RSV vaccine, which has faced stiff competition from a rival shot by GSK. Despite lower-than-anticipated sales of Abrysvo, Pfizer ( NYSE:PFE ) remains committed to advancing its respiratory syncytial virus (RSV) vaccine portfolio. Analysts remain cautiously optimistic about Pfizer's trajectory, with JP Morgan's Chris Schott emphasizing the importance of stronger new launch performance and pipeline progress in reshaping investor sentiment.
NYSE:PFE
by DEXWireNews
FDA Approves Pfizer’s First Gene TherapyIn a landmark decision, the Food and Drug Administration (FDA) has given its stamp of approval to Pfizer's groundbreaking gene therapy for hemophilia B, marking a pivotal moment in the field of genetic medicine. Hemophilia B, a rare inherited bleeding disorder affecting thousands in the U.S., has long posed significant challenges for patients and caregivers due to its debilitating nature and the cumbersome treatment regimens it necessitates. Unveiling Beqvez: Pfizer's newly approved gene therapy, Beqvez, heralds a paradigm shift in hemophilia B treatment. Unlike conventional methods that require frequent infusions of factor IX, Beqvez offers a one-time solution, empowering patients to produce the crucial clotting factor independently. This innovative approach not only promises to alleviate the burden of regular treatments but also holds the potential to prevent and control bleeding more effectively. Transformative Impact: The approval of Beqvez represents a ray of hope for individuals grappling with hemophilia B, offering a lifeline towards improved quality of life and reduced medical complexities. Dr. Adam Cuker, from Penn Medicine’s Comprehensive and Hemophilia Thrombosis Program, underscores the transformative potential of Beqvez, emphasizing its ability to mitigate both medical and treatment-related challenges over the long term. Pfizer's Strategic Maneuver For Pfizer ( NYSE:PFE ), the approval of Beqvez marks a strategic triumph in its quest to diversify beyond the realm of COVID therapeutics. With a keen focus on gene and cell therapies, Pfizer ( NYSE:PFE ) is positioning itself at the forefront of medical innovation, aiming to redefine the treatment landscape across various disease domains. The company's investment in Beqvez underscores its commitment to pioneering solutions that address unmet medical needs and enhance patient outcomes. Navigating Challenges: While the approval of Beqvez heralds a new era in hemophilia B treatment, it also presents formidable challenges. The exorbitant price tag of $3.5 million raises concerns about accessibility and affordability, echoing debates surrounding the broader issue of healthcare equity. Furthermore, logistical hurdles and adoption barriers may impede widespread uptake, underscoring the need for comprehensive strategies to ensure equitable access to this groundbreaking therapy. Looking Ahead: As Pfizer ( NYSE:PFE ) embarks on this groundbreaking journey with Beqvez, the company's pipeline continues to brim with promise. From experimental antibodies to gene therapies targeting other genetic disorders like Duchenne muscular dystrophy, Pfizer remains at the vanguard of medical innovation, driving forward the frontier of personalized medicine. As the healthcare landscape evolves, Beqvez stands as a beacon of hope, illuminating a path towards a future where genetic therapies revolutionize the treatment paradigm, one patient at a time.
NYSE:PFELong
by DEXWireNews
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Despite short-term challenges like revenue and earnings declines in the current quarter, Pfizer (PFE) maintains a positive long-term growth trajectory. With optimistic earnings estimates for the full fiscal year, consistent EPS beats, and a discounted valuation relative to peers, Pfizer represents an attractive investment opportunity. Trade Idea: Buy Pfizer (PFE) Long-term growth potential remains strong despite short-term setbacks. Positive earnings outlook for the full fiscal year indicates resilience. Consistent EPS beats highlight Pfizer's ability to manage its bottom line effectively. Discounted valuation compared to industry peers suggests potential for stock price appreciation. Consider a medium to long-term investment horizon to capture Pfizer's growth prospects and maximize returns.
NYSE:PFELong
by Elite_Forex
PFIZER, INC (PFE) 1WOverall Trend: PFIZER, INC (PFE) Downtrend: The price being below the 50, 100, and 200-day moving averages since January 2023 suggests a downtrend. Price Movement: Consolidation: The current price of $25.69 near the 52-week low indicates a possible consolidation phase. Without a one-week chart, it's difficult to say for sure if the price is bouncing off support or continuing the downtrend. Volume: Average Volume: The volume of 64.54 million is around average, which doesn't provide a strong directional signal. Momentum Indicators: RSI (30.00 - 40.00): This indicates oversold territory. Oversold readings don't guarantee an immediate rebound, but they do suggest the stock might be undervalued based on recent price movements. MACD : The MACD signals being below the histogram since January 2023 suggests a downtrend in momentum. This aligns with the price being below the moving averages. Summary: The technical analysis of PFE is mixed. The downtrend, oversold RSI, and MACD below the histogram are bearish indicators. However, the consolidation around the 52-week low and average volume makes it difficult to predict a clear direction in the short term. Here are some additional things to consider: News and Events: Look for any recent news or events that might be impacting the stock price. Fundamental Analysis: Consider factors like PFE's earnings, debt levels, and overall business outlook. Chart Patterns: Analyze the one-week chart for any specific chart patterns that might provide further clues about the stock's direction. Disclaimer: This analysis is for informational purposes only and should not be considered financial advice. Always do your own research before making any investment decisions. "In this business if you're good, you're right six times out of ten. You're never going to be right nine times out of ten. I've found that when the market's going down and you buy funds wisely, at some point in the future you will be happy. You won't get there by reading: "Now is the time to buy". Tendencia general: Tendencia bajista: El hecho de que el precio esté por debajo de las medias móviles de 50, 100 y 200 días desde enero de 2023 sugiere una tendencia bajista. Movimiento de precios: Consolidación: El precio actual de 25,69 dólares cerca del mínimo de 52 semanas indica una posible fase de consolidación. Sin un gráfico de una semana, es difícil decir con certeza si el precio está rebotando en el soporte o continúa la tendencia bajista. Volumen: Volumen medio: El volumen de 64,54 millones está en torno a la media, lo que no proporciona una señal direccional fuerte. Indicadores de impulso: RSI (30.00 - 40.00): Esto indica territorio de sobreventa. Las lecturas de sobreventa no garantizan un repunte inmediato, pero sí sugieren que las acciones podrían estar infravaloradas en función de los recientes movimientos de precios. MACD: El hecho de que el MACD señale que está por debajo del histograma desde enero de 2023 sugiere una tendencia bajista en el impulso. Esto se alinea con que el precio está por debajo de las medias móviles. Resumen: El análisis técnico de PFE es mixto. La tendencia bajista, el RSI sobrevendido y el MACD por debajo del histograma son indicadores bajistas. Sin embargo, la consolidación en torno al mínimo de 52 semanas y el volumen medio hace que sea difícil predecir una dirección clara a corto plazo. Aquí hay algunas cosas adicionales a considerar: Noticias y eventos: Busque noticias o eventos recientes que puedan estar afectando el precio de las acciones. Análisis fundamental: Considere factores como las ganancias de PFE, los niveles de deuda y las perspectivas generales del negocio. Patrones gráficos: Analice el gráfico de una semana en busca de patrones gráficos específicos que puedan proporcionar más pistas sobre la dirección de la acción. Descargo de responsabilidad: Este análisis es solo para fines informativos y no debe considerarse asesoramiento financiero. Siempre haga su propia investigación antes de tomar cualquier decisión de inversión. "En este negocio, si eres bueno, tienes razón seis de cada diez veces. Nunca vas a acertar nueve de cada diez veces. He descubierto que cuando el mercado está bajando y compras acciones sabiamente, en algún momento en el futuro serás feliz. No llegarás allí leyendo: "Ahora es el momento de comprar".
NYSE:PFELong
by rodulfox
SasanSeifi 💁‍♂ PFE /DAILY ⏭ $28 /$30Hey there,✌ NYSE:PFE In the daily timeframe, as observed, the price is currently fluctuating within the $25 range following a prolonged downtrend. The long-term trendline has been broken, and we can consider the following scenario: if the demand range is maintained, the price may experience positive fluctuations up to the $28 range. Then, if the $28 ceiling is breached and stabilizes above it, we may witness an upward trend and a new higher HIGH beyond the $28 ceiling. The desired targets in the long term and potential trends are also indicated in the attached image. The $25 demand range is crucial for the envisaged scenario. Moreover, if the price penetrates below the $25 range, the likelihood of further correction increases. This is not financial advice. Always do your research before making any investment decisions.❗ Sure, if you have any more questions or need further clarification, feel free to ask. I'm here to help!✌ if you found my analysis helpful, I would appreciate it if you could show your support by liking and commenting. Thank you!🙌
NYSE:PFELong
by SasanSeifi
PFE - LONG(1h timeframe) DETAILS: the price made a traingle and brokeout ,it broke also the two emas (100,200) and continued the breakout , i wanted to see a big bullish candle to enter , when i entered the bullish candle tried to break very strong resistence area and swing high ( i tought that the candle will break this area and the swing , because of the breakout) the price got affected and went down in my opinion the price eventually will break the swing and the resistence area. the sl is below the two emas and 0.5 fib.
NYSE:PFELong
by omeramran67
Pfizer (PFE): Shocking Downward Spiral - $11 Target In Sight?Pfizer (PFE): NYSE:PFE At Pfizer, we believe that Wave (2) has not yet completed because Wave B precisely hits the 138% level and structurally does not make sense unless we see a breakthrough of the invalidation zone of the potential subordinate Wave (i) at about $41.62. However, we must form at least a double bottom at $11, which is our minimum expectation for Pfizer. For the downward movement, we need to examine more closely how far it can actually fall, but $11 is our minimum expectation. The only scenario that would make sense here might be a short position for a possible subordinate Wave (iv) between $36.9 and $41.62. Subsequently, for the overarching Wave ((iii)), we expect another decline to a minimum of $22.64 and, in our opinion, a maximum of $9.56. Entering a long position could be too risky over a longer period. For those looking to trade in the short term, there might be a bottom at $25.61, leading up to the potential target zone for Wave (iv). After that, we expect the downtrend to continue, and personally, we are not positioning ourselves long due to the significant risk.
NYSE:PFEShort
by freeguy_by_wmc